The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …

Metformin is a widely used biguanide drug due to its safety and low cost. It has been used
for over 60 years to treat type 2 diabetes at the early stages because of its outstanding ability …

Metformin is one of the most popular oral glucose-lowering medications, widely considered
to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

Since its inception in 2004, the “Clinical Practice Guidelines for the Treatment of Diabetes”
has attempted to promote evidence-based, rational, efficient and standardized clinical …

Over the last few years, incretin‐based therapies have emerged as important agents in the
treatment of type 2 diabetes (T2D). These agents exert their effect via the incretin system …

Insulin resistance in muscle and liver and-cell failure represent the core pathophysiologic
defects in type 2 diabetes. It now is recognized that the-cell failure occurs much earlier and …

Aim GLP‐1 receptor agonists (RAs) may cause nausea, vomiting or diarrhoea. The aim of
this study was to assess the risk of adverse events (AEs) with GLP‐1 RAs and their relation …

People with type 2 diabetes form a heterogeneous group. Consequently, treatment
regimens and therapeutic targets should be individualized. The treatment of type 2 diabetes …

Objective: The aim is to provide guidelines for the evaluation and management of adults with
hypoglycemic disorders, including those with diabetes mellitus. Evidence: Using the …